ArticleNature2014
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 238 citations in OpenAlex.
- DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.The Journal of investigative dermatology · 2026Article
- Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Cancer research · 2026Article
- The role of galectins in modulating the tumor microenvironment and driving metastasis in skin cancers.Biological research · 2026Review
- Disruption of the reciprocal inhibitory relationship between cell proliferation and melanogenesis in pet murine melanoma cells by ultraviolet radiation.Frontiers in veterinary science · 2026Article
- Knowledge and awareness about the harmful effects of sun exposure on the skin and sun safety methods used in the adult Kuwaiti population: A questionnaire-based study.JAAD international · 2025Article
- Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Uncovering minimal pathways in melanoma initiation.Nature communications · 2025Article
- Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFOncogene · 2025Article
- Review
- Assessment of the Influence of UVR in Cutaneous Melanoma.Photodermatology, photoimmunology & photomedicine · 2025Review
- Individualized Neoantigen-Directed Melanoma Therapy.American journal of clinical dermatology · 2025Review
- Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.Cancer research · 2025Article
- Loss of Lkb1 cooperates with BrafMolecular oncology · 2025Article
- Generation of a genetically engineered porcine melanoma model featuring oncogenic control through conditional Cre recombination.Scientific reports · 2025Article
- Article
- Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy.Molecular biomedicine · 2024Review
- FAK loss reduces BRAFeLife · 2024Article
- Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal transduction and targeted therapy · 2024Review
- Review
- Transactivation of Met signaling by oncogenic Gnaq drives the evolution of melanoma in Hgf-Cdk4 mice.Cancer gene therapy · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Cutaneous melanoma is epidemiologically linked to ultraviolet radiation (UVR), but the molecular mechanisms by which UVR drives melanomagenesis remain unclear. The most common somatic mutation in melanoma is a V600E substitution in BRAF, which is an early event. To investigate how UVR accelerates oncogenic BRAF-driven melanomagenesis, we used a BRAF(V600E) mouse model. In mice expressing BRAF(V600E) in their melanocytes, a single dose of UVR that mimicked mild sunburn in humans induced clonal expansion of the melanocytes, and repeated doses of UVR increased melanoma burden. Here we show that sunscreen (UVA superior, UVB sun protection factor (SPF) 50) delayed the onset of UVR-driven melanoma, but only provided partial protection. The UVR-exposed tumours showed increased numbers of single nucleotide variants and we observed mutations (H39Y, S124F, R245C, R270C, C272G) in the Trp53 tumour suppressor in approximately 40% of cases. TP53 is an accepted UVR target in human non-melanoma skin cancer, but is not thought to have a major role in melanoma. However, we show that, in mice, mutant Trp53 accelerated BRAF(V600E)-driven melanomagenesis, and that TP53 mutations are linked to evidence of UVR-induced DNA damage in human melanoma. Thus, we provide mechanistic insight into epidemiological data linking UVR to acquired naevi in humans. Furthermore, we identify TP53/Trp53 as a UVR-target gene that cooperates with BRAF(V600E) to induce melanoma, providing molecular insight into how UVR accelerates melanomagenesis. Our study validates public health campaigns that promote sunscreen protection for individuals at risk of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.